Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 3/20 | 0.50 |
| ▸ | SLC6A9 | P48067 | 14/20 | 0.48 |
| ▸ | HTR1A | P08908 | 1/20 | 0.45 |
| ▸ | HTR2A | P28223 | 1/20 | 0.41 |
| ▸ | HTR2B | P41595 | 1/20 | 0.41 |
| ▸ | KDM1A | O60341 | 1/20 | 0.41 |
| ▸ | RCOR1 | Q9UKL0 | 1/20 | 0.41 |
| ▸ | OPRM1 | P35372 | 6/20 | 0.41 |
| ▸ | SLC6A5 | Q9Y345 | 3/20 | 0.40 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL2336054 | 0.99 | HTR2C (0.51) | HTR2CSLC6A9HTR1AHTR2AHTR2B | |
| SCHEMBL2875597 | 0.91 | HTR1A (0.47) | HTR2CSLC6A9HTR1AHTR2AHTR2B | |
| SCHEMBL5557035 | 0.84 | SLC6A9 (0.56) | HTR2CSLC6A9OPRM1SLC6A5KCNH2 | |
| SCHEMBL9963256 | 0.82 | SLC6A9 (0.51) | SLC6A9HTR1AHTR2BOPRM1SLC6A5 | |
| SCHEMBL1138335 | 0.80 | SLC6A9 (0.56) | SLC6A9OPRM1SLC6A5OPRL1KCNH2 | |
| SCHEMBL5561878 | 0.74 | SLC6A9 (0.58) | SLC6A9OPRM1SLC6A5KCNH2 | |
| SCHEMBL5556903 | 0.74 | SLC6A9 (0.58) | SLC6A9OPRM1SLC6A5KCNH2 | |
| SCHEMBL1138347 | 0.74 | SLC6A9 (0.58) | SLC6A9OPRM1SLC6A5KCNH2 | |
| Hydrochloric Acid SCHEMBL5562493 | 0.73 | SLC6A9 (0.57) | SLC6A9OPRM1SLC6A5KCNH2 | |
| SCHEMBL5556904 | 0.72 | SLC6A9 (0.55) | SLC6A9OPRM1SLC6A5KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2356101-A1 | PYRIMIDINE AND TRIAZINE SULFONAMIDE DERIVATES AS B1 BRADYKININ RECEPTOR (B1R) INHIBITORS FOR TREATING PAIN | Grünenthal GmbH (DE) | 2011-08-17 | — | — | EP | claimed |
| WO-2010046109-A1 | PYRIMIDINE AND TRIAZINE SULFONAMIDE DERIVATES AS B1 BRADYKININ RECEPTOR (B1R) INHIBITORS FOR TREATING PAIN | Grünenthal GmbH (DE) | 2010-04-29 | — | — | WO | claimed |
| EP-2356101-B1 | PYRIMIDINE- AND TRIAZINE-SULFONAMIDE DERIVATIVES AS BRADYKININ B1 RECEPTOR (B1R) INHIBITORS FOR THE TREATMENT OF PAIN | GRUENENTHAL GMBH (DE) | 2013-02-27 | — | — | EP | disclosed |
| US-8269000-B2 | Substituted pyrimidine and triazine compounds | GRUENENTHAL GMBH (DE) | 2012-09-18 | — | — | US | disclosed |
| US-8269000-B2 | Substituted pyrimidine and triazine compounds | GRUENENTHAL GMBH (DE) | 2012-09-18 | — | — | US | disclosed |
| US-20100173889-A1 | Substituted Pyrimidine and Triazine Compounds | GRUENENTHAL GMBH (DE) | 2010-07-08 | — | — | US | disclosed |
| US-20100173889-A1 | Substituted Pyrimidine and Triazine Compounds | GRUENENTHAL GMBH (DE) | 2010-07-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100173889-A1 | Substituted Pyrimidine and Triazine Compounds | ADORA2B, CCNB1, TYMS | HTR2C 1129/4885SLC6A9 2859/4885HTR1A 199/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.